The Medicare Advantage Trade Unravels as Regulators Pull the Profit Lever

Wall Street bet on a policy windfall for health insurers, but instead got hit with regulatory whiplash. UnitedHealth GroupUNH

stunned investors by forecasting its first annual revenue decline since 1989 just as the Centers for Medicare and Medicaid Services (CMS) proposed keeping Medicare Advantage rates nearly flat in 2027. The shock erased more than $60B in market value, as shares plunged ~20%.

The pullback begins: CEO Stephen Hemsley told analysts the company has “taken a critical look across all our products and our US market positions,” a review that is now translating into painful cuts. UnitedHealth plans to shed up to 2.8M members across its commercial, Medicare, and Medicaid plans, while Optum Health will close or sell about 550 care sites, shrinking its footprint by roughly 20%. CFO Wayne DeVeydt confirmed some medical practices will be shuttered and others sold to hospitals or providers as margins erode in a unit that once drove profit growth.

• Revenue is expected to fall at both UnitedHealthcare’s insurance unit and its Optum services division, marking the first time both segments have declined at the same time.
• The timing is brutal, coming just as UNH tries to rebuild investor confidence after last year’s collapse and as Trump’s latest Medicare proposal lands a shock to the entire industry.

The Medicare Reckoning

The selloff spread beyond UnitedHealth Group, with HumanaHUM

, CVS HealthCVS

, and Elevance HealthELV

sliding as Wall Street repriced the sector for tighter margins. The iShares US Healthcare Providers ETF also fell, signaling growing acceptance that government-backed growth is stalling. Medicare Advantage remains critical, covering nearly 34M people and driving $494B in government payments in 2024. Against that backdrop, UnitedHealthcare CEO Tim Noel called the CMS rate decision “disappointing,” saying the company will work with the CMS to avoid a “profoundly negative impact on seniors’ benefits and access to care.”

• The proposed 0.09% rate increase would add only about $700M in 2027 payments, a sharp comedown for an industry used to seeing annual increases measured in billions.
• CMS Administrator Dr. Mehmet Oz defended the move, saying the changes are meant to make Medicare Advantage work better for patients while updating risk adjustment to protect taxpayers.

Policy trapdoor: The selloff signals more than frustration with one rate cycle and instead marks the end of an era when insurers relied on friendly regulators for steady payment growth. Wall Street had bet on the Trump administration reversing Biden-era pullbacks, but that optimism faded as Donald Trump openly targeted insurers and Mehmet Oz moved to hold Medicare Advantage rates flat. JP Morgan’s Lisa Gill noted preliminary rates often rise later, but Evercore’s Ann Hynes warned the proposal could delay any double-digit EPS recovery into 2027. For an industry built on predictable government growth, the economic cushion is slowly fading away.